Cytotoxic Anticancer Drugs: Models and Concepts for Drug Discovery and Development: Proceedings of the Twenty-Second Annual Cancer Symposium Detroit, Michigan, USA — April 26–28, 1990: Developments in Oncology, cartea 68
Editat de Frederick A. Valeriote, Thomas H. Corbett, Laurence H. Bakeren Limba Engleză Hardback – 31 mar 1992
Of particular significance has been the initiation of renewed efforts in the area of natural product drug discovery, where the discovery of new cytotoxics is very promising at the moment. A number of major changes have occurred during the last decade in research on drug discovery of cytotoxic agents. Critical reviews of a number of the models and concepts underlying drug discovery represented a continuous thread throughout the meeting, being constantly discussed in terms of their advantages, disadvantages and capabilities of discovering solid tumor active anticancer agents.
A recent development which is to be much applauded and which portends to great discoveries is the new relationship formed between Government, University of Industry. The NCDDG mechanism which stimulates this interaction is an inexpensive manner to greatly magnify the drug discovery and development effort nationally. Cytotoxic Anticancer Drugs: Models and Concepts for Drug Discovery and Development represents a forum which will become the major mode for bringing together these three different components in the equation to regularly discuss new results and ideas.
Toate formatele și edițiile | Preț | Express |
---|---|---|
Paperback (1) | 1392.89 lei 6-8 săpt. | |
Springer Us – 8 oct 2012 | 1392.89 lei 6-8 săpt. | |
Hardback (1) | 1399.91 lei 6-8 săpt. | |
Springer Us – 31 mar 1992 | 1399.91 lei 6-8 săpt. |
Din seria Developments in Oncology
- 5% Preț: 354.68 lei
- 5% Preț: 378.36 lei
- 5% Preț: 345.71 lei
- 5% Preț: 1078.48 lei
- 5% Preț: 354.83 lei
- 5% Preț: 1106.88 lei
- 5% Preț: 3129.77 lei
- 5% Preț: 365.10 lei
- 5% Preț: 368.31 lei
- 5% Preț: 1393.97 lei
- 5% Preț: 369.06 lei
- 5% Preț: 362.40 lei
- 5% Preț: 1083.51 lei
- 5% Preț: 362.20 lei
- 15% Preț: 594.37 lei
- 5% Preț: 1401.69 lei
- 5% Preț: 1100.23 lei
- 5% Preț: 368.31 lei
- 5% Preț: 1392.18 lei
- 5% Preț: 711.04 lei
- 5% Preț: 701.34 lei
- 5% Preț: 1400.11 lei
- 5% Preț: 706.55 lei
- 5% Preț: 361.49 lei
- 5% Preț: 1399.20 lei
- 5% Preț: 1079.19 lei
- 5% Preț: 3771.24 lei
- 5% Preț: 1082.08 lei
- 5% Preț: 1100.90 lei
- 5% Preț: 1395.43 lei
- 5% Preț: 1415.01 lei
- 5% Preț: 1095.92 lei
Preț: 1399.91 lei
Preț vechi: 1473.59 lei
-5% Nou
Puncte Express: 2100
Preț estimativ în valută:
267.99€ • 275.62$ • 222.33£
267.99€ • 275.62$ • 222.33£
Carte tipărită la comandă
Livrare economică 18 februarie-04 martie
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9780792316299
ISBN-10: 0792316290
Pagini: 409
Ilustrații: XVII, 409 p.
Dimensiuni: 155 x 235 x 24 mm
Greutate: 0.77 kg
Ediția:1992
Editura: Springer Us
Colecția Springer
Seria Developments in Oncology
Locul publicării:New York, NY, United States
ISBN-10: 0792316290
Pagini: 409
Ilustrații: XVII, 409 p.
Dimensiuni: 155 x 235 x 24 mm
Greutate: 0.77 kg
Ediția:1992
Editura: Springer Us
Colecția Springer
Seria Developments in Oncology
Locul publicării:New York, NY, United States
Public țintă
ResearchCuprins
1. DRUG DISCOVERY— 1990.- 2. DATA DISPLAY AND ANALYSIS STRATEGIES FOR THE NCI DISEASE-ORIENTED IN VITRO ANTITUMOR DRUG SCREEN.- 3. DISCOVERY OF SOLID TUMOR ACTIVE AGENTS USING A SOFT-AGAR-COLONY-FORMATION DISK-DIFFUSION- ASSAY.- 4. THYMIDYLATE SYNTHASE INHIBITION OF MODIFIED QUINAZOLINE ANTIFOLATES.- 5. DNA-MINOR GROOVE BINDING ANTICANCER AGENTS.- 6. 2-((ARYLMETHYL)AMIN0)-l,3-PR0PANEDI0LS (AMAPS); DISCOVERY, SELECTION AND DEVELOPMENT OF FOUR CLINICAL CANDIDATES.- 7. MECHANISM-BASED APPROACHES TO CANCER DRUG DISCOVERY.- 8. DISCOVERY AND BULK PRODUCTION OF NATURAL PRODUCTS WITH ANTICANCER ACTIVITY: THE ROLE OF CHEMICAL ECOLOGY.- 9. CHEMICAL APPROACHES TO IMPROVED RADIOTHERAPY.- 10. LARGE SCALE ANTICANCER DRUG SCREENING AT STERLING DRUG INC..- 11. ARE ANTISENSE OLIG0NUCLEOTIDES THERAPEUTIC AGENTS OF THE FUTURE?.- 12. SUPERCOMPUTER AIDED DRUG DESIGN: APPLICATION IN ONCOLOGY AND AIDS.- 13. EXTRACHROMOSOMAL DNA AS A TARGET FOR DRUG DEVELOPMENT.- 14. PROSPECTIVE EVALUATION OF A PREDICTIVE MODEL FOR PLASMA CONCENTRATION-VERSUS-TIME PROFILES OF INVESTIGATIONAL ANTICANCER DRUGS IN PATIENTS.- 15. AGENT-DIRECTED PRECLINICAL TOXICOLOGY FOR NEW ANTINFOPLASTIC DRUGS.- 16. PRECLINICAL STUDIES WITH BREQUINAR SODIUM: A NOVEL ANTICANCER AGENT.- 17. DIPHTHERIA TOXIN-RELATED PEPTIDE HORMONE FUSION PROTEINS: NEW TOXINS WITH THERAPEUTIC POTENTIAL.- 18. ANTI-GROWTH FACTOR RECEPTOR ANTIBODIES AS THERAPY FOR CANCER.- 19. REGULATION OF POLYAMINE BIOSYNTHETIC ACTIVITY AND HOMEOSTASIS AS A NOVEL ANTIPROLIFERATIVE STRATEGY.- 20. ESPERAMICIN A1 (BMY28175)- A NOVEL ANTI- TUMOR AGENT OF THE DIYNE-ENE CLASS.- 21. MODIFIED 2-TUMOR (L1210, COLON 38) ASSAY TO SCREEN FOR SOLID TUMOR SELECTIVE AGENTS.- 22. 5-FLUOROURACIL: SCHEDULE OPTIMIZATION IN METASTATIC COLORECTAL CANCER.- 23. PRECLINICAL ANTITUMOREFFICACY OF TAXOTERE (RP56976, NSC 628503), A TAXOL ANALOG AND OF RP60475 (NSC645008), A NEW BENZOPYRI- DOINDOLE.